Anaptys Sees Positive Trial Results for Imsidolimad Psoriasis Treatment
By Chris Wack
Anaptys said Monday that it saw positive top-line results from its global Phase 3 trial evaluating the safety and efficacy of imsidolimab in patients with generalized pustular psoriasis flares.
The stock was halted at $19.25 in premarket trading.
The biotechnology company said that investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling after a single dose of 750mg IV imsidolimab.
Top-line data also demonstrate a favorable safety and tolerability profile.
All adverse effects reported in imsidolimab-treated patients were mild or moderate and balanced across imsidolimab-treated versus placebo patients. No serious or severe adverse effects were reported in imsidolimab-treated patients.
Anaptys plans to present comprehensive data from the trial in the second half of 2024. The company anticipates filing a biologics license application with the U.S. Food and Drug Administration by the third quarter of 2024.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
October 09, 2023 08:28 ET (12:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
How to Invest Like Warren Buffett
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025